Exagen Inc. (XGN), a specialist in autoimmune testing, has announced that it has garnered conditional approval from the New York State Department of Health for its latest biomarker assays targeting systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). These assays are set for a commercial release in January 2025.
The company highlighted that these new biomarkers will be integrated into its AVISE CTD platform. Together, these enhancements are anticipated to significantly augment the clinical utility of AVISE CTD, equipping healthcare providers with the necessary insights to accurately diagnose patients, thereby reducing the diagnostic journey for those with autoimmune disorders.
For the fourth quarter, Exagen Inc. is forecasting a net loss between $3.4 million and $4.4 million, while expecting revenue to be in the range of $13.3 million to $13.8 million.
